Treatment of B-cell cancers has been transformed by cluster ... CAR-T cells to recognize and attack through two antigens, CD19 and CD20, thus producing deeper and more durable responses in ...

The only near-clinical project that CRGX has at this time is CRG-023, a tri-specific, tri-cistronic CAR T-cell therapy designed to bind CD19, CD20, and CD22, which are all markers of B-cell ...

Lyell Immunopharma’s ($LYEL) jumped over 8% on Friday as investors’ interest surged. Despite posting unimpressive Q4 results ...

The Phase III MITIGATE trial demonstrated that Uplizna (inebilizumab) significantly reduces the risk of flares, lowers ...

Less than 18 months after listing on the Nasdaq, CAR-T therapy developer CARGO Therapeutics has abandoned its development ...

CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia ... different antigens, such as CD19, CD20, and ALK. This suggests that second ...

Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...

2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that KJ-C2219, an allogeneic CAR-T therapy targeting CD19/CD20, ...

Lyell Immunopharma, Inc.’s LYEL share price has surged by 20.28%, which has investors questioning if this is right time to sell.

Lyell Immunopharma, Inc.’s LYEL share price has dipped by 11.67%, which has investors questioning if this is right time to buy.